Evidence map›Paper›PMID 31989625›Full record

Trial reportAllergy2021

Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study.

Thomas Stranzl, Henrik Ipsen, Lars Harder Christensen, Thomas Eiwegger, Niels Johansen, Kaare Lund, Peter Sejer Andersen

Abstract readClinical Trial, Phase IIILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Thomas StranzlALK-Abelló A/S, Hørsholm, Denmark.
Henrik IpsenHICON, Hillerød, Denmark.
Lars Harder ChristensenALK-Abelló A/S, Hørsholm, Denmark.
Thomas EiweggerDivision of Immunology and Allergy, Department of Pediatrics, Food allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Canada.ORCID 0000-0002-2914-7829
Niels JohansenALK-Abelló A/S, Hørsholm, Denmark.
Kaare LundPapermill Medical, Copenhagen, Denmark.ORCID 0000-0002-3520-7744
Peter Sejer AndersenALK-Abelló A/S, Hørsholm, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HypersensitivitySublingual ImmunotherapyAllergensAnimalsAntigens, DermatophagoidesHumansImmunoglobulin EPyroglyphidaeTabletsTreatment OutcomeAllergensAntigens, DermatophagoidesImmunoglobulin ETabletscinical effectDer p 23diagnosisHDM SLIT-tablets

Identifiers

PMID31989625
PMCPMC8246736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.